ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • inflammation and synovitis
  • inflammation and synovium
  • inflammation and systemic lupus erythematosus (SLE)
  • inflammation and systemic sclerosis
  • inflammation and temporal arteritis
  • inflammation and tendonitis/bursitis
  • inflammation and therapy
  • inflammation and thrombosis
  • inflammation and tocilizumab
  • inflammation and tofacitinib
  • inflammation and tophaceous gout
  • inflammation and transcription factor
  • inflammation and transforming growth factor
  • inflammation and tumor necrosis factor (TNF)
  • inflammation and ultrasound
  • inflammation and uric acid
  • inflammation and uveitis
  • inflammation and vasculitis
  • inflammation and viruses
  • inflammation and vitamins
  • inflammatory arthritis
  • inflammatory arthritis and adverse events
  • inflammatory arthritis and inflammatory bowel disease (IBD)
  • inflammatory arthritis and infliximab
  • inflammatory arthritis and innate immunity
  • Inflammatory arthritis and insulin resistance
  • inflammatory arthritis and integrins
  • inflammatory arthritis and interdisplinary
  • inflammatory arthritis and interleukins (IL)
  • inflammatory arthritis and lipids
  • inflammatory arthritis and lymph node
  • inflammatory arthritis and macrophages
  • inflammatory arthritis and magnetic resonance imaging (MRI)
  • inflammatory arthritis and mesenchymal stem cells
  • inflammatory arthritis and metabolism
  • inflammatory arthritis and mitochondria
  • Inflammatory arthritis and monocytes
  • inflammatory arthritis and morbidity and mortality
  • inflammatory arthritis and myopathy
  • inflammatory arthritis and nanomedicine
  • inflammatory arthritis and natural killer (NK) cells
  • inflammatory arthritis and neutrophils
  • inflammatory arthritis and nod-like receptor (NLR)
  • inflammatory arthritis and nursing roles
  • inflammatory arthritis and occupational therapy
  • inflammatory arthritis and osteoarthritis
  • inflammatory arthritis and osteoclasts
  • inflammatory arthritis and patient outcomes
  • inflammatory arthritis and patient preferences
  • inflammatory arthritis and Patient Satisfaction
  • inflammatory arthritis and PD-1
  • inflammatory arthritis and platelets
  • inflammatory arthritis and pregnancy
  • inflammatory arthritis and primary care
  • inflammatory arthritis and proteomics
  • inflammatory arthritis and quality of care
  • inflammatory arthritis and randomized trials
  • inflammatory arthritis and registry
  • inflammatory arthritis and regulatory cells
  • inflammatory arthritis and remission
  • inflammatory arthritis and rheumatoid arthritis
  • Inflammatory arthritis and rheumatoid arthritis (RA)
  • inflammatory arthritis and risk assessment
  • inflammatory arthritis and skill development
  • inflammatory arthritis and skin
  • inflammatory arthritis and spondylarthritis
  • inflammatory arthritis and statins
  • inflammatory arthritis and synovial cells
  • Inflammatory arthritis and thyroid
  • inflammatory arthritis and transcription factor
  • inflammatory arthritis and treatment guidlelines
  • inflammatory arthritis and tumor necrosis factor (TNF)
  • inflammatory arthritis and ultrasonography
  • inflammatory arthritis and ultrasound
  • inflammatory arthritis and viruses
  • inflammatory arthritis and women's health
  • inflammatory back pain
  • inflammatory back pain and back pain
  • inflammatory back pain and non-radiographic
  • Inflammatory back pain and psoriatic arthritis
  • inflammatory back pain and spondylarthritis
  • Inflammatory Bowel Disease
  • inflammatory bowel disease (IBD)
  • inflammatory bowel disease (IBD) and anti-TNF therapy
  • inflammatory bowel disease (IBD) and inflammatory cytokines
  • inflammatory bowel disease (IBD) and infliximab
  • inflammatory bowel disease (IBD) and interleukins (IL)
  • inflammatory bowel disease (IBD) and juvenile idiopathic arthritis (JIA)
  • inflammatory bowel disease (IBD) and magnetic resonance imaging (MRI)
  • inflammatory bowel disease (IBD) and microbiome
  • inflammatory bowel disease (IBD) and PAD
  • inflammatory bowel disease (IBD) and psoriasis
  • inflammatory bowel disease (IBD) and psoriatic arthritis
  • inflammatory bowel disease (IBD) and rheumatic disease
  • inflammatory bowel disease (IBD) and rheumatoid arthritis (RA)
  • inflammatory bowel disease (IBD) and spondylarthritis
  • inflammatory bowel disease (IBD) and tumor necrosis factor (TNF)
  • Inflammatory bowel disease (IBD) and vasculitis
  • inflammatory cytokines
  • inflammatory cytokines and autoantibodies
  • inflammatory cytokines and bacteria infection
  • inflammatory cytokines and flow cytometry
  • inflammatory cytokines and gout
  • inflammatory cytokines and interferons
  • inflammatory cytokines and interleukins (IL)
  • inflammatory cytokines and juvenile idiopathic arthritis (JIA)
  • inflammatory cytokines and matrix metalloproteinase (MMP)
  • inflammatory cytokines and metabolism
  • inflammatory cytokines and microparticles
  • inflammatory cytokines and prognostic factors
  • inflammatory cytokines and prostaglandins
  • inflammatory cytokines and rheumatoid arthritis (RA)
  • inflammatory cytokines and small molecules
  • inflammatory cytokines and synovial cells
  • inflammatory cytokines and systemic sclerosis
  • inflammatory disease
  • Inflammatory Eye Disease
  • Inflammatory Eye Disease and patient-reported outcome measures
  • inflammatory myopathy
  • inflammatory myositis
  • inflammatory myositis and interferons
  • inflammatory myositis and interstitial lung disease
  • inflammatory myositis and myositis
  • inflammatory myositis and ovarian
  • inflammatory myositis and prognostic factors
  • Inflammatory myositis and quality of life
  • Inflammatory myositis and statin-induced myopathies
  • Inflammatory myositis and statins
  • Inflammatory rheumatic disease
  • inflammatory rheumatic diseases
  • inflammed synovial fibroblast
  • infliximab
  • infliximab and anti-TNF therapy
  • infliximab and antibodies
  • infliximab and Clinical Response
  • infliximab and drug therapy
  • infliximab and efficacy
  • infliximab and infusions
  • infliximab and methotrexate (MTX)
  • Infliximab and outcome measures
  • infliximab and pharmacokinetics
  • infliximab and prognostic factors
  • infliximab and psoriatic arthritis
  • infliximab and rheumatic disease
  • infliximab and rheumatoid arthritis
  • infliximab and rheumatoid arthritis (RA)
  • infliximab and safety
  • Infliximab and sarcoidosis
  • infliximab and spondylarthritis
  • infliximab and surgery
  • infliximab and switch
  • infliximab and thalidomide
  • infliximab and tocilizumab
  • infliximab and treatment
  • infliximab and tuberculosis
  • infliximab and tumor necrosis factor (TNF)
  • infliximab and uveitis
  • Influenza
  • influenza and Biologics
  • influenza and education
  • influenza and immunogenicity
  • influenza and vaccine hesitancy
  • informatics
  • information technology
  • information technology and methotrexate (MTX)
  • information technology and registry
  • information technology and website
  • infusions
  • infusions and health care cost
  • infusions and Medicare
  • infusions and patient outcomes
  • infusions and reactions
  • infusions and rheumatoid arthritis (RA)
  • Infusions and rituximab
  • infusions and safety
  • Inheritance
  • inhibitor
  • inhibitor and autoimmune
  • injection and procedure
  • injury
  • injury and neuropsychiatric disorders
  • injury and osteoarthritis
  • injury and polymorphism
  • injury and rehabilitation
  • injury and rheumatoid arthritis (RA)
  • innate immunity
  • innate immunity and inflammation
  • innate immunity and interferons
  • innate immunity and interleukins (IL)
  • innate immunity and juvenile idiopathic arthritis (JIA)
  • innate immunity and macrophage activation syndrome
  • innate immunity and migration inhibitory factor (MIF)
  • innate immunity and monocytes
  • innate immunity and mouse model
  • innate immunity and myositis
  • innate immunity and neuropsychiatric disorders
  • innate immunity and nod-like receptor (NLR)
  • innate immunity and ontogeny
  • innate immunity and prognostic factors
  • innate immunity and psoriatic arthritis
  • First |
  • « Previous Page
  • 26
  • 27
  • 28
  • 29
  • 30
  • [31]
  • 32
  • 33
  • 34
  • 35
  • 36
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology